Dose related and predictable |
Dryness of skin and mucous membranes including nose, eyes, and lips |
Of particular concern |
Teratogenicity, during treatment and for 6 weeks after stopping |
Mood change—highly publicised, unproven, but cause for concern |
Uncommon |
Facial erythema, eczema, hair loss, and photosensitivity |
Myalgia and arthralgia |
Abnormalities of liver function |
Elevation of triglycerides and cholesterol values |
Bacterial overgrowth, particularly Staphylococcus aureus |
Benign intracranial hypertension |